In vitro responses of human peripheral blood mononuclear cells to whole‐cell, particulate and soluble extracts of Leishmania promastigotes

Whole‐cell and soluble extracts of Leishmania promastigotes have both been used as skin test antigens and have also been tested as vaccine candidates. However, the differences in antigenicity between soluble and particulate Leishmania fractions are not known. We evaluated in vitro responses of PBMC from 30 American tegumentary leishmaniasis (ATL) patients and seven noninfected donors to different antigen preparations from Leishmania promastigotes, namely Leishmania amazonensis and L. braziliensis whole‐cell extracts, as well as soluble and particulate fractions of L. amazonensis. All Leishmania antigen preparations stimulated significantly higher proliferation and interferon (IFN)‐γ production (but not interleukin (IL)‐10 production) in PBMC from the leishmaniasis patients than in cells from the control subjects. The L. braziliensis whole‐cell extract stimulated significantly higher cell proliferation and IFN‐γ production than the L. amazonensis whole‐cell extract in the group of patients but not in the control group. This result can be explained by the fact that the patients were infected with L. braziliensis. Again in the group of patients, the PBMC proliferative responses as well as the levels of IFN‐γ and IL‐10 stimulated by L. amazonensis whole‐cell extract were significantly greater than those elicited by the L. amazonensis soluble fraction but were not significantly different from those elicited by the L. amazonensis particulate fraction. We found a higher antigenicity of the particulate fraction as compared to the soluble fraction, what suggests that the antigens present in the particulate fraction account for most of the antigenicity of whole‐cell Leishmania promastigote antigen extracts.

[1]  F. Modabber,et al.  Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[2]  Syamal Roy,et al.  Kinetoplastid Membrane Protein-11 DNA Vaccination Induces Complete Protection against Both Pentavalent Antimonial-Sensitive and -Resistant Strains of Leishmania donovani That Correlates with Inducible Nitric Oxide Synthase Activity and IL-4 Generation: Evidence for Mixed Th1- and Th2-Like Responses , 2005, The Journal of Immunology.

[3]  S. Sundar,et al.  Immunostimulatory cellular responses of cured Leishmania‐infected patients and hamsters against the integral membrane proteins and non‐membranous soluble proteins of a recent clinical isolate of Leishmania donovani , 2005, Clinical and experimental immunology.

[4]  Thomas Rades,et al.  Lipid based particulate formulations for the delivery of antigen , 2005, Immunology and cell biology.

[5]  F. Conceição-Silva,et al.  Differential interferon- gamma production characterizes the cytokine responses to Leishmania and Mycobacterium leprae antigens in concomitant mucocutaneous leishmaniasis and lepromatous leprosy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  P. Tsagozis,et al.  Dendritic Cells Pulsed with Peptides of GP63 Induce Differential Protection against Experimental Cutaneous Leishmaniasis , 2004, International journal of immunopathology and pharmacology.

[7]  P. Desjeux.  Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.

[8]  M. Rogers,et al.  New insights into the developmental biology and transmission mechanisms of Leishmania. , 2004, Current molecular medicine.

[9]  U. Lopes,et al.  The T-cell anergy induced by Leishmania amazonensis antigens is related with defective antigen presentation and apoptosis. , 2004, Anais da Academia Brasileira de Ciencias.

[10]  R. Lainson,et al.  Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. , 2004, Memorias do Instituto Oswaldo Cruz.

[11]  F. Conceição-Silva,et al.  Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  J. Donelson,et al.  The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. , 2003, Molecular and biochemical parasitology.

[13]  K. Anam,et al.  Characterization of Leishmania donovani Antigens Encapsulated in Liposomes That Induce Protective Immunity in BALB/c Mice , 2002, Infection and Immunity.

[14]  P. Machado,et al.  Up-Regulation of Th1-Type Responses in Mucosal Leishmaniasis Patients , 2002, Infection and Immunity.

[15]  F. Modabber,et al.  Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial , 2002, International journal of dermatology.

[16]  A. B. Reis,et al.  A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. , 2001, Acta tropica.

[17]  D. Soldati,et al.  Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice. , 2001, Vaccine.

[18]  P. Desjeux.  The increase in risk factors for leishmaniasis worldwide. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[19]  U. Mörtberg,et al.  Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors , 2001, Clinical and experimental immunology.

[20]  O. Fernandes,et al.  American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics , 2000, International journal of dermatology.

[21]  A. Kibbi,et al.  Cutaneous leishmaniasis: clinical features and diagnosis. , 1999, Clinics in dermatology.

[22]  V. Toledo,et al.  Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. , 1999, Vaccine.

[23]  K. B. Marzochi,et al.  Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. , 1998, Memorias do Instituto Oswaldo Cruz.

[24]  F. Silveira,et al.  T cell responses to crude and defined leishmanial antigens in patients from the Lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia , 1998, Parasite immunology.

[25]  F. Liew,et al.  Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters , 1997, Infection and immunity.

[26]  W. Mayrink,et al.  Montenegro skin test--evaluation of the composition and stability of the antigen preparation. , 1996, Memorias do Instituto Oswaldo Cruz.

[27]  F. Modabber.  Vaccines against leishmaniasis. , 1995, Annals of tropical medicine and parasitology.

[28]  F. Conceição-Silva,et al.  Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. , 1995, The American journal of tropical medicine and hygiene.

[29]  F. Liew,et al.  Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. , 1995, Immunology.

[30]  T. Theander,et al.  Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2‐like response to gp63 and Thl‐like response to lipophosphoglycan‐ associated protein in cells from cured visceral leishmaniasis patients , 1994, Clinical and experimental immunology.

[31]  H. Rocha,et al.  Characterization of T cell responses to purified leishmania antigens in subjects infected with Leishmania chagasi. , 1994, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[32]  E. Cupolillo,et al.  A general classification of New World Leishmania using numerical zymotaxonomy. , 1994, The American journal of tropical medicine and hygiene.

[33]  W. McMaster,et al.  Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Ulrich,et al.  The clinical and immunological spectrum of American cutaneous leishmaniasis. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[35]  J. Burns,et al.  Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. , 1992, Journal of immunology.

[36]  S. Reed,et al.  Evaluation of the stability of a soluble intradermal skin test antigen preparation in American visceral leishmaniasis. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[37]  A. Sher,et al.  Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. , 1987, Journal of Immunology.

[38]  C. Pirmez,et al.  Human american cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. , 1986, Clinical and experimental immunology.

[39]  O. Verde,et al.  Characterization of the cellular immune response in American cutaneous leishmaniasis. , 1983, Clinical immunology and immunopathology.

[40]  E. Carvalhoa,et al.  Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis , 2002 .

[41]  M. N. Melo,et al.  A field trial of a vaccine against American dermal leishmaniasis. , 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene.